CGH
PCVX icon

Crossmark Global Holdings’s Vaxcyte PCVX Stock Holding History

Crossmark Global Holdings’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,672
Closed -$277K – 1334
2024
Q2 		$277K Buy
3,672
+535
+17% +$36.4K 0.01% 1098
2024
Q1 		$214K Buy
+3,137
New +$217K ﹤0.01% 1257

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Crossmark Global Holdings's PCVX Position: Q3 2024 in Review

Crossmark Global Holdings sold out of Vaxcyte (PCVX) in Q3 2024, closing a stake of 3,672 shares — an estimated $277K sold.

Crossmark Global Holdings first reported a position in PCVX in Q1 2024 and held it in 2 quarters. The position peaked at $277K in Q2 2024. 328 funds tracked by Wall St. Rank hold PCVX as of Q3 2024.

  • Crossmark Global Holdings reported no remaining Vaxcyte position as of Q3 2024 after selling out during the quarter.
  • Crossmark Global Holdings sold 3,672 Vaxcyte shares in Q3 2024, an estimated $277K.
  • Crossmark Global Holdings first reported a position in Vaxcyte in Q1 2024 and held it in 2 quarters.
  • Crossmark Global Holdings's Vaxcyte position peaked at $277K in Q2 2024.
  • 328 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2024.

Based on Crossmark Global Holdings's 13F filing for Q3 2024, filed 4 Nov 2024.